Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company

Core Insights - Lifeward is positioning itself as a MedTech platform with a clear path to profitability and long-term Biotech potential through a strategic partnership with Oramed Pharmaceuticals [1][2] Investment and Financial Structure - Lifeward will receive up to $47 million in strategic investment from Oramed and another investor, which includes equity, convertible notes, milestone-based funding, and warrant coverage [2][14] - The investment structure aims to support Lifeward's journey to profitability while allowing for selective investments in high-value innovations [2] Technology Acquisition - Lifeward is acquiring Oramed's Protein Oral Delivery (POD™) technology, which targets the $600+ billion injectable drugs market, including the potential for ORMD-0801 to become the first commercialized oral insulin [1][3] - The POD™ technology is designed to transform injectable biological therapies into oral medications, addressing a significant market opportunity in diabetes and other metabolic diseases [3][10] Clinical Development and Management - Oramed will manage and fund the clinical development of the POD™ technology, allowing Lifeward to focus on profitability and cash generation while retaining exposure to biotech opportunities [4][8] - The POD™ technology has shown promise in clinical trials, with the lead drug candidate ORMD-0801 achieving significant results in reducing HbA1c levels [12] Strategic Goals and Diversification - The partnership with Oramed marks the beginning of Lifeward's broader diversification strategy across medical technology and biotechnology [5] - Lifeward aims to achieve sustainable profitability from existing FDA-approved products while building a balanced biomedical portfolio that combines near-term revenue with long-term biotech innovation [6][7]